• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Emergent BioSolutions Inc. Common Stock (NY:EBS)

    5.435 +0.125 (+2.35%)
    Streaming Delayed Price Updated: 10:48 AM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Emergent BioSolutions Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Reports Second Quarter 2026 Financial Results
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
    Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources 
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Participate in Upcoming Investor Conferences
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Reports First Quarter 2026 Financial Results
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
    Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan 
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
    New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency 
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
    From Emergent BioSolutions
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.